Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 742 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-small Cell Lung Cancer Stage I Clear all
Completed Phase 1 Interventional

Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer

NCT00014430
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 9, 2026, 5:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

NCT03948100
View directory record Official record
Conditions
Esophageal Carcinoma, Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Yoga
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 5:21 AM EDT
Not yet recruiting Phase 2 Interventional

Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

NCT07720167
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

NCT01801111
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Erlotinib, Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • Fullerton, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

NCT00655655
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 9, 2026, 5:21 AM EDT
Withdrawn Phase 1 Interventional

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT01971489
View directory record Official record
Conditions
Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Buparlisib, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

NCT00019825
View directory record Official record
Conditions
Esophageal Cancer, Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
Interventions
decitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 9, 2026, 5:21 AM EDT
Active, not recruiting Not applicable Interventional

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT02194738
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7,458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1655
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer

NCT00128622
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
denileukin diftitox, recombinant fowlpox-CEA(6D)/TRICOM vaccine, therapeutic autologous dendritic cells
Biological
Lead sponsor
H. Kim Lyerly
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

NCT02022982
View directory record Official record
Conditions
KRAS Mutant Non-Small Cell Lung Cancer, Solid Tumors
Interventions
Palbociclib, PD-0325901
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00005850
View directory record Official record
Conditions
Anxiety Disorder, Depression, Fatigue, Lung Cancer
Interventions
cisplatin, fluoxetine, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
42
States / cities
Anniston, Alabama • San Diego, California • Washington D.C., District of Columbia + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 9, 2026, 5:21 AM EDT
Terminated Phase 1 Interventional

Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel

NCT02439346
View directory record Official record
Conditions
Medical Oncology
Interventions
BAY1143269 tablet
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Dallas, Texas • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 9, 2026, 5:21 AM EDT
Recruiting Phase 3 Interventional

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

NCT07388524
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection, Computed Tomography, Patient Observation
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
96
States / cities
Beverly Hills, California • Los Angeles, California • Tarzana, California + 80 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)

NCT01100931
View directory record Official record
Conditions
NSCLC, Solid Tumors
Interventions
YM155, Carboplatin, Paclitaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00778167
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cixutumumab, erlotinib hydrochloride, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Denver, Colorado • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 9, 2026, 5:21 AM EDT
Recruiting Phase 1 Interventional

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NCT06400472
View directory record Official record
Conditions
Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
Interventions
Sofe-M, bevacizumab, carboplatin, Itraconazole, pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
11
States / cities
Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

NCT02927301
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
19
States / cities
Duarte, California • Santa Monica, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 2 Interventional

Video-Assisted Surgery in Treating Patients With Non-small Cell Lung Cancer

NCT00003692
View directory record Official record
Conditions
Lung Cancer
Interventions
therapeutic thoracoscopy, video-assisted surgery
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
112
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 72 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function

NCT00002901
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2010 · Synced Oct 9, 2026, 5:21 AM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Results available

Phase I Combination Ixabepilone + Cisplatin

NCT00832117
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ixabepilone, Cisplatin
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New Brunswick, New Jersey • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

NCT00019006
View directory record Official record
Conditions
Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage III Non-small Cell Lung Cancer, Stage I Pancreatic Cancer, Stage II Non-small Cell Lung Cancer, Stage IVB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage IVA Pancreatic Cancer
Interventions
Detox-B adjuvant, ras peptide cancer vaccine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 9, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

NCT01324479
View directory record Official record
Conditions
Solid Tumors
Interventions
INC280
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
5
States / cities
Fayetteville, Arkansas • Chicago, Illinois • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 9, 2026, 5:21 AM EDT